Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CELC

Celcuity Inc

Oct 22 • 04:00PM ET

70.04

+4.54 6.93 %

Healthcare • Biotechnology • USA • NASD

Peers: GILD ACAD NBIX BIIB BMRN EXEL ALKS INCY BHVN IONS

| Held by: VTI IWM VXF IWO SCHA XBI VTWO DWAS IDNA IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.45	Insider Own	30.34%	Shs Outstand	38.91M	Perf Week	40.00%
Market Cap	2.97B	Forward P/E	-	EPS next Y	-4.34	Insider Trans	0.47%	Shs Float	29.55M	Perf Month	33.41%
Enterprise Value	2.90B	PEG	-	EPS next Q	-1.02	Inst Own	76.16%	Short Float	16.47%	Perf Quarter	398.51%
Income	-148.71M	P/S	-	EPS this Y	-40.23%	Inst Trans	-4.05%	Short Ratio	2.86	Perf Half Y	532.70%
Sales	0.00M	P/B	61.42	EPS next Y	-9.36%	ROA	-62.47%	Short Interest	4.87M	Perf YTD	435.06%
Book/sh	1.14	P/C	17.65	EPS next 5Y	21.67%	ROE	-134.54%	52W High	83.00 -15.61%	Perf Year	342.45%
Cash/sh	3.97	P/FCF	-	EPS past 3/5Y	-8.60% -31.53%	ROIC	-103.52%	52W Low	7.57 824.62%	Perf 3Y	585.32%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	11.49% 7.97%	Perf 5Y	1194.64%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-25.61%	Oper. Margin	-	ATR (14)	5.66	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	4.58	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	68.95	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	4.58	EPS Q/Q	-68.04%	SMA20	33.99%	Beta	0.68	Target Price	82.50
Payout	-	Debt/Eq	2.24	Sales Q/Q	-	SMA50	32.33%	Rel Volume	1.00	Prev Close	65.50
Employees	87	LT Debt/Eq	2.24	Earnings	Aug 14 AMC	SMA200	196.14%	Avg Volume	1.70M	Price	70.04
IPO	Sep 20, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.61% -	Trades		Volume	1,698,468	Change	6.93%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-22-25	Initiated	Guggenheim	Buy	$110
Jul-01-25	Resumed	Stifel	Buy	$30
Jul-22-24	Initiated	Leerink Partners	Outperform	$29
Feb-22-24	Initiated	Stifel	Buy	$40
Dec-08-23	Initiated	H.C. Wainwright	Buy	$27
Oct-08-21	Initiated	Canaccord Genuity	Buy	$50
Sep-07-21	Initiated	Jefferies	Buy	$48
Jul-29-21	Initiated	Cowen	Outperform
Jul-27-21	Initiated	Needham	Buy	$50
Jan-28-21	Reiterated	H.C. Wainwright	Buy	$14 → $18
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$11 → $14
May-11-20	Resumed	Craig Hallum	Buy
Nov-20-18	Initiated	H.C. Wainwright	Buy	$36

Show Previous Ratings

Oct-21-25 12:55PM	Celcuity (CELC) Hits Fresh Record High on Stellar Breast Cancer Drug Trial Result (Insider Monkey) -7.20%
Oct-20-25 04:13PM	Top 1% Celcuity Stock Shoots To Record High On Roche-Rivaling Breast Cancer Results (Investor's Business Daily) +35.84%
10:02AM	Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results (Investor's Business Daily)
Oct-18-25 04:30AM	Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
04:30AM	Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial (GlobeNewswire)
04:30AM	Loading…
04:30AM	Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer ("mCRPC") (GlobeNewswire)
Oct-07-25 09:00AM	Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion (PR Newswire)
Sep-30-25 12:47PM	Celcuity Inc. (CELC)'s FDA NDA for Gedatolisib Accepted Under RTOR, Accelerating Review (Insider Monkey) -5.13%
Sep-22-25 09:15AM	Celcuity to Present Results from the Pivotal Phase 3 VIKTORIA-1 Trial at the 2025 European Society for Medical Oncology (ESMO) Congress (GlobeNewswire)
Sep-09-25 04:01PM	Celcuity Announces Upsized Senior Secured Term Loan Facility of $500 Million with Innovatus Capital Partners and Oxford Finance (GlobeNewswire) -7.96%
Aug-27-25 04:05PM	Celcuity to Initiate NDA Submission of Gedatolisib in PIK3CA Wild-Type Cohort in HR+/HER2- Advanced Breast Cancer Under FDA's Real-Time Oncology Review Program (GlobeNewswire) +9.29%
Aug-15-25 03:24AM	Celcuity Inc (CELC) Q2 2025 Earnings Call Highlights: Navigating Losses and Strategic Advances (GuruFocus.com)
Aug-14-25 04:01PM	Celcuity Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-25 07:05AM	Celcuity Inc. Schedules Release of Second Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jul-30-25 06:30AM	Celcuity Inc. Announces Pricing of Concurrent Public Offerings of 2.750% Convertible Senior Notes Due 2031 and Common Stock and Pre-Funded Warrants (GlobeNewswire)
03:46PM	Loading…
Jul-29-25 03:46PM	Biotech Underdogs Line Up for Pivotal Shots at Game-Changing Cancer Treatments (PR Newswire)
02:15PM	Up 215% YTD, Should You Grab This Growth Stock Before Its Too Late? (Barchart)
09:56AM	Relay Therapeutics has positive read from Celcuity data, says Barclays (TipRanks)
09:43AM	Celcuity (CELC) Skyrockets 167% on Breast Cancer Treatment Trial (Insider Monkey)
Jul-28-25 04:02PM	Celcuity Inc. Announces Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock (GlobeNewswire) +167.18%
02:09PM	Celcuity stock rallies on Phase III breast cancer trial progress (Clinical Trials Arena)
11:55AM	Top Stock Movers Now: Nike, Cheniere Energy, Revvity, and More (Investopedia)
10:09AM	Celcuity Stock Triples on Positive Breast Cancer Treatment Study (Investopedia)
09:42AM	Celcuity Stock Skyrockets On Breakthrough Trial Data For Heavily Pretreated Breast Cancer (Benzinga)
08:15AM	Celcuity shares triple on late-stage results for breast cancer therapy (BioPharma Dive)
07:00AM	Celcuity Announces Clinically Meaningful Improvement in Both Progression-Free Survival ("PFS") Primary Endpoints from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial (GlobeNewswire)
Jul-25-25 04:05PM	Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
Jul-24-25 04:01PM	Celcuity Announces First Patient Dosed in Phase 3 VIKTORIA-2 Clinical Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer (GlobeNewswire)
Jul-14-25 07:05AM	Celcuity Announces Issuance of New Patent for Gedatolisib that Extends Patent Exclusivity into 2042 (GlobeNewswire)
Jun-30-25 07:05AM	Celcuity Reports Clinical Data from Two Early Phase Studies of Gedatolisib (GlobeNewswire) +6.46%
07:05AM	Loading…
May-21-25 07:05AM	Celcuity To Present at Upcoming TD Cowen and Jefferies Investor Conferences (GlobeNewswire)
May-15-25 09:56AM	Q1 2025 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Celcuity Inc (CELC) Q1 2025 Earnings Call Highlights: Navigating Increased Losses and Strategic ... (GuruFocus.com)
May-14-25 04:01PM	Celcuity Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
May-07-25 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2025 Financial Results and Webcast/Conference Call (GlobeNewswire)
Apr-01-25 08:41AM	Q4 2024 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) -8.11%
07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
03:03AM	Celcuity Inc (CELC) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges with ... (GuruFocus.com)
Mar-31-25 10:50PM	Celcuity Inc. (CELC) Q4 2024 Earnings Call Transcript (Seeking Alpha)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-24-25 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Feb-27-25 10:10AM	Oncology Breakthroughs: How Cancer Research Is Advancing in 2025 (PR Newswire)
Feb-25-25 07:05AM	Celcuity to Participate at Upcoming Cowen and Leerink Investor Conferences (GlobeNewswire) -8.99%
Dec-11-24 07:05AM	Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in Combination with Palbociclib and Endocrine Therapy at the 2024 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-15-24 02:20AM	Celcuity Inc (CELC) Q3 2024 Earnings Call Highlights: Clinical Milestones and Financial Challenges (GuruFocus.com) -10.28%
Nov-14-24 04:01PM	Celcuity Inc. Reports Third Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-12-24 07:05AM	Celcuity Inc. To Present at Upcoming Stifel and Jefferies Investor Conferences (GlobeNewswire)
Nov-07-24 07:05AM	Celcuity Inc. Schedules Release of Third Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Oct-09-24 06:26PM	Celcuity Inc (CELC) Q2 2024 Earnings Call Highlights: Strategic Advancements Amid Rising Expenses (GuruFocus.com) -5.83%
Oct-07-24 09:10PM	Morgan Stanley's Strategic Reduction in Celcuity Inc Holdings (GuruFocus.com)
Sep-10-24 09:55AM	Can Celcuity (CELC) Climb 87.59% to Reach the Level Wall Street Analysts Expect? (Zacks)
Aug-20-24 12:00PM	Celcuity (CELC) Upgraded to Buy: Here's Why (Zacks)
Aug-14-24 04:01PM	Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-07-24 07:05AM	Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jun-03-24 04:01PM	Celcuity To Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -5.25%
May-30-24 07:36AM	Celcuity Announces Pricing of Underwritten Common Stock Offering (GlobeNewswire)
07:00AM	Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for HR+/HER2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing (GlobeNewswire)
May-16-24 11:54AM	Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating (MT Newswires)
03:08AM	Celcuity Inc (CELC) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges and ... (GuruFocus.com)
May-15-24 08:55PM	CELC Stock Earnings: Celcuity Beats EPS for Q1 2024 (InvestorPlace)
06:04PM	Celcuity Q1 Net Loss Widens; Shares Rise After Hours (MT Newswires)
04:01PM	Celcuity Inc. Reports First Quarter Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 07:05AM	Celcuity Inc. Schedules Release of First Quarter 2024 Financial Results and Webcast/Conference Call (GlobeNewswire)
May-03-24 12:15PM	Top Five Cancer Types Dominate New US Cases as Biotech Sector Eyes $314B Market by 2032 (PR Newswire)
Apr-04-24 07:05AM	Celcuity To Present at Upcoming Needham and Stifel Investor Conferences (GlobeNewswire)
Apr-01-24 01:38PM	Celcuity Inc. (NASDAQ:CELC) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-28-24 06:51AM	Q4 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents) +18.94%
Mar-27-24 08:53PM	CELC Stock Earnings: Celcuity Beats EPS for Q4 2023 (InvestorPlace)
05:51PM	Celcuity Inc (CELC) Reports Full Year 2023 Financial Results and Highlights Key Developments (GuruFocus.com)
04:01PM	Celcuity Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-21-24 11:17AM	Why Celcuity (CELC) Might Surprise This Earnings Season (Zacks)
Mar-20-24 07:05AM	Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Mar-06-24 07:05AM	Celcuity to Participate in Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Feb-28-24 07:05AM	Celcuity to Participate in Cowen's 44th Annual Health Care Conference (GlobeNewswire)
Feb-22-24 04:05PM	Celcuity Announces First Patient Dosed in Phase 1b/2 CELC-G-201 Clinical Trial of Gedatolisib for the Treatment of Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Feb-20-24 07:05AM	Celcuity Appoints Eldon Mayer as Chief Commercial Officer (GlobeNewswire) -5.51%
Dec-06-23 08:30AM	Celcuity Presents Preclinical Data on Therapeutic Effects of Gedatolisib in Breast Cancer Models at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-01-23 11:02AM	Celcuity to Present Preclinical Data for Gedatolisib at the 2023 San Antonio Breast Cancer Symposium (GlobeNewswire)
Nov-22-23 08:05AM	Celcuity to Participate in the 6th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-14-23 10:50AM	Celcuity Inc. (NASDAQ:CELC) Q3 2023 Earnings Call Transcript (Insider Monkey) +10.10%
Nov-13-23 09:41PM	Q3 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
10:54AM	Celcuity Inc (CELC) Reports Q3 2023 Financial Results and Strategic Developments (GuruFocus.com)
07:05AM	Celcuity Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Nov-06-23 07:30AM	Celcuity Inc. Schedules Release of Third Quarter 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Nov-01-23 07:05AM	Celcuity To Present at Upcoming Stifel and Jefferies Investor Conferences (GlobeNewswire) -5.35%
Oct-18-23 09:15AM	Celcuity Inc. Announces $50 Million Private Placement (ACCESSWIRE) +11.38%
Sep-21-23 04:43PM	The 7 Best Short-Squeeze Stocks to Buy Now: September 2023 (InvestorPlace)
Sep-07-23 04:05PM	Celcuity to Host Virtual Science Day for Investors (GlobeNewswire)
Sep-06-23 07:10PM	7 Short-Squeeze Stocks That Actually Might Make Sense (InvestorPlace)
Aug-22-23 04:05PM	Celcuity Enters into a Clinical Trial Collaboration and Supply Agreement with Bayer to Provide Nubeqa® (darolutamide) for Planned Phase 1b/2 Clinical Trial (GlobeNewswire)
04:01PM	Celcuity Announces Plan to Conduct Phase 1b/2 Clinical Trial in Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Aug-11-23 05:58AM	Q2 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 04:04PM	Celcuity Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Updates (GlobeNewswire)
Aug-03-23 07:30AM	Celcuity Inc. Schedules Release of Second Quarter 2023 Financial Results and Webcast/Conference Call (GlobeNewswire)
Jul-31-23 08:00AM	Celcuity to Participate in the BTIG Virtual Biotechnology Conference 2023 (GlobeNewswire)
Jul-27-23 06:51AM	Celcuity Inc. (NASDAQ:CELC) stock most popular amongst individual investors who own 23%, while private equity firms hold 22% (Simply Wall St.)
Jun-20-23 09:02AM	Celcuity Set to Join Russell 2000 and 3000 Indexes (ACCESSWIRE)
May-24-23 08:00AM	Celcuity to Participate in Upcoming Craig-Hallum and Jefferies Investor Conferences (ACCESSWIRE)
07:59AM	Insiders of Celcuity Getting Good Value On Their US$1.6m Investment \ (Simply Wall St.)
May-16-23 06:26AM	Q1 2023 Celcuity Inc Earnings Call (Thomson Reuters StreetEvents)

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BAKER BROS. ADVISORS LP	10% Owner	Sep 08 '25	Buy	56.27	170,100	9,571,319	7,211,484	Sep 10 04:06 PM
Dalvey David	Director	Jul 28 '25	Sale	43.98	100,000	4,397,603	125,000	Jul 30 04:15 PM
Dalvey David	Director	Jul 28 '25	Sale	45.12	9,325	420,767	0	Jul 30 04:15 PM
Brightstone Venture Capital Fu	Director	Jul 28 '25	Proposed Sale	43.98	100,000	4,397,605		Jul 28 02:52 PM
Dalvey David	Director	Jul 28 '25	Proposed Sale	45.12	9,325	420,766		Jul 28 02:00 PM
Furcht Leo	Director	Dec 02 '24	Option Exercise	3.60	250	900	10,750	Dec 03 06:11 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CELC

Celcuity Inc

Upgrade your FINVIZ experience